In the Literature
Febrile neutropenia (FN) is a serious side effect of many cancer treatments and can lead to severe infection and sepsis with potentially fatal consequences.
Biosimilars are poised to bring significant cost-savings opportunities in oncology, while maintaining high-quality patient care.
Patients with anemia and lower-risk myelodysplastic syndromes (MDS) in whom first-line erythropoiesis-stimulating agents (ESAs) are not effective generally become transfusion dependent.
Lost Earnings from Cancer-Related Deaths Cost the United States $94 Billion in 2015
- Venetoclax plus Rituximab Improves Outcomes in Chronic Lymphocytic Leukemia
- Lay Navigation Reduces Medicare Costs, Resource Utilization
- Adding Antiandrogen Therapy Improves Survival in Recurrent Prostate Cancer
- Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
- Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
- Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
- Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
- ASCO Issues Guidelines for Developing Clinical Pathways That Promote Value-Based Care
- Second Cancer Risk Is High After Hodgkin Lymphoma
- Cancer Screening May Not Save Lives, a New Analysis Suggests s
Hepatocellular carcinoma is the second most common cause of cancer-related death and occurs most often in patients with cirrhosis. Vascular endothelial growth factor (VEGF) plays an important role in tumor growth and angiogenesis, and is overexpressed in patients with hepatocellular carcinoma.
Results 1 - 9 of 9